Cabozantinib is used for medullary thyroid carcinoma. And advanced renal cell carcinoma in people who have previously received anti-angiogenic therapy. Currently, it is undergoing clinical trials to treat prostate cancer, bladder cancer, ovarian cancer, brain cancer, melanoma, breast cancer, non-small cell lung cancer, pancreatic cancer and hepatocellular carcinoma.